An interventional study of Biologic Mesh and Synthetic Mesh in Hernia Inguinal and Biologic Mesh, sponsored by Xiangya Hospital of Central South University. Not yet recruiting at 1 site in China. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-06-16.
Sponsored by Xiangya Hospital of Central South University · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 27 studies in Hernia, Inguinal with a site in China — 5 open to participants now, 5 under way, none of them phase 3. Hernia, Inguinal · China.
Among the 27 studies in Hernia, Inguinal with a site in China, this one is the 18th largest by planned enrollment of the 24 interventional ones that give a count, is one of 2 that started in 2026, is one of 20 with no phase, and was the 26th registered.
545 studies on the registry are indexed under Hernia, Inguinal; 91 are open to participants now.
Browse Hernia, Inguinal studies →5 of the 27 studies in Hernia, Inguinal with a site in China are open now. Recruiting first, the newest first:
Nanchong Central Hospital · Sites in China
Ages 18+ · Women only
The Second Affiliated Hospital of Kunming Medical University · Sites in China
Ages 18–80
Xiangya Hospital of Central South University · Sites in China
Ages up to 14
Nanchong Central Hospital · Sites in China
Ages 18–80
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 54 Hernia, Inguinal studies recruiting now, 30 (56%) set no upper age limit and 16 (30%) stop at 75 or younger; 16 take children under 18; 9 take healthy volunteers.
This study: 18 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
27 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 2 · Phase 3 1 · Phase 4 1
First in 2000; this study’s year is marked. 2 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 90 is close to the median of 90 across 397 interventional studies indexed under Hernia, Inguinal.
Median enrollment 117 across the 24 interventional studies, 300 across the 3 observational. Of the 10 that completed or were terminated, 1 (10%) have results posted.
This tab as a report to print or save as PDF → With an account.
2 of 27 have an industry lead sponsor. The 10 most frequent:
Xiangya Hospital of Central South University is the lead sponsor of 177 studies on the registry; 80 are open to participants now.
Xiangya Hospital of Central South University has 2 studies filed under Hernia, Inguinal — fewer than ten, so there is no comparison to draw.
1 of the studies in Hernia, Inguinal with a site in China that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07936981Xiangya Hospital of Central South UniversityPain Assessment After Pediatric Indirect Inguinal Hernia Surgery | 2027-10-30 |
Add it to your calendar (.ics) → With an account.
Among the 27 studies in Hernia, Inguinal with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Inguinal hernia is one of the most common conditions in general surgery. In clinical practice, surgeons frequently face a dilemma: during the evaluation of a patient with unilateral symptomatic inguinal hernia, a contralateral asymptomatic defect is discovered-either preoperatively on physical examination or intraoperatively during laparoscopy. The question then becomes: how should this incidental finding be managed? Epidemiological data show that the incidence of such contralateral asymptomatic hernias can be as high as 20%. The management strategy for these hernias has changed considerably over time. Although traditional "watchful waiting" was once widely adopted, long-term follow-up studies have demonstrated that approximately 70% of asymptomatic patients eventually require surgery due to symptom progression, and increasing age is associated with higher surgical risks. Consequently, with the widespread adoption of laparoscopic techniques, simultaneous repair of asymptomatic hernias during the initial surgery has become a common clinical choice.
However, this decision raises a critical question: how can the surgeon balance the need to repair the existing anatomical defect against the risk of introducing new long-term complications from the intervention? This makes the choice of repair material particularly important. Currently, synthetic polypropylene meshes, with their proven effectiveness in reducing recurrence rates, are considered the gold standard for inguinal hernia repair. However, as permanent implants, they may be associated with long-term complications-chronic postoperative pain and foreign body sensation, which affect patients' long-term quality of life.
Biologic meshes offer a different option. Derived from decellularized extracellular matrix, they are designed as temporary scaffolds that guide autologous tissue regeneration and ultimately degrade. Theoretically, this avoids a permanent foreign body reaction and may reduce long-term discomfort. Nevertheless, the clinical value of biologic meshes in inguinal hernia repair remains controversial. Some studies suggest that biologic meshes reduce chronic pain and improve quality of life; others show no difference in pain or recurrence rates compared with synthetic meshes. Meta-analyses have not demonstrated clear superiority of biologic over synthetic meshes in overall complications, recurrence, or chronic pain, and the heterogeneity among existing studies is high.
The BIOLAP randomized clinical trial, published in JAMA Surgery in 2025, provided high-level evidence for symptomatic bilateral hernias. It showed that in laparoscopic inguinal hernia repair, biologic mesh did not significantly reduce postoperative pain. Moreover, it was associated with a significantly higher 2-year recurrence rate (11.2% vs. 2.5%) and a higher seroma rate (33.4% vs. 21.6%). However, a key question remains: can these conclusions be directly extrapolated to the setting of contralateral asymptomatic hernia repair, where the therapeutic goal is to maximize long term comfort rather than to relieve existing symptoms? The investigators previously conducted an exploratory single-center randomized controlled study (n=52, BiSOH) that addressed this question preliminarily. In that trial, the biologic mesh group had significantly lower inguinal pain scores at both 1 month and 6 months, with pain decreasing over time in both groups. Quality of life measured by SF-36 was significantly better in the biologic mesh group at both follow-up time points, and the EQ-5D score was higher at 6 months. These findings suggest that biologic mesh may offer advantages in chronic pain control and quality of life for occult hernia repair, contrasting with the BIOLAP conclusions. However, the single center design and methodological limitations prevented confirmation of the primary endpoint difference, highlighting the need for a multicenter, high-quality clinical trial.
Currently, international guidelines lack high level evidence on the optimal mesh type for simultaneous repair of contralateral asymptomatic hernias. Therefore, this multicenter, randomized, single-blinded, parallel-controlled trial was designed to compare biologic versus synthetic meshes in this specific scenario. The hypothesis is that the use of a biologic mesh (porcine UBM/SIS composite) reduces chronic pain on the asymptomatic side at 6 months without increasing recurrence, compared with a synthetic mesh (self-gripping polyester).
The biologic mesh is a porcine urinary bladder matrix and small intestinal submucosa composite (UBM/SIS) manufactured by ZR Medtech (Suzhou, China). It is a non-cross-linked, acellular, collagenous matrix produced through patented decellularization and antigen removal processes. It has been used for various soft tissue defect repairs.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients in this arm receive a biological mesh (porcine urinary bladder matrix/small intestinal submucosa composite) for the contralateral asymptomatic hernia repair. The symptomatic side is repaired uniformly with a synthetic mesh (self-gripping polyester) in all patients. Both sides are repaired during the same laparoscopic TAPP procedure.
Device: Biologic Mesh
Patients in this arm receive a synthetic mesh (self-gripping polyester) for the contralateral asymptomatic hernia repair. The symptomatic side is repaired uniformly with the same synthetic mesh (self-gripping polyester) in all patients. Both sides are repaired during the same laparoscopic TAPP procedure.
Device: Synthetic Mesh
A non-cross-linked, acellular, collagenous matrix derived from porcine urinary bladder matrix and small intestinal submucosa (UBM/SIS). Unlike permanent synthetic meshes, this biological mesh is designed to gradually degrade and be replaced by autologous tissue, potentially reducing chronic pain and foreign body sensation. Used for contralateral asymptomatic hernia repair during laparoscopic TAPP.
A large-pored, lightweight, self-gripping polyester mesh. Used as active comparator for contralateral asymptomatic hernia repair during laparoscopic TAPP.
Chronic pain on the asymptomatic side at 6 months after surgery
Pain will be measured using a numerical rating scale (NRS, 0-10 points) and documented separately for each side. At the 6 month follow up, patients will assess the most severe pain experienced in the past week for the left and right inguinal regions independently. The primary endpoint is the NRS score reported for the asymptomatic side.
Time frame: 6 months after surgery
Pain assessment
NRS scores (0-10) assessed on each side at postoperative day 1 (before discharge) and at the 1-month follow-up visit.
Time frame: Postoperative day 1 and 1 month after surgery
Short-Form Inguinal Pain Questionnaire (SF-IPQ)
Validated questionnaire assessing pain characteristics, frequency, and impact on daily activities. Scores range from 0 to 12. Higher scores indicate more severe pain or functional limitation.
Time frame: 1 month and 6 months after surgery
Quality of life (SF-36)
Short Form 36 (SF-36) assesses physical and mental health components. Scores range from 0 to 100. Higher scores indicate better quality of life.
Time frame: Preoperatively, and at 1 month and 6 months after surgery
Recurrence on the asymptomatic side
Clinical recurrence defined as a reducible mass on physical examination, confirmed by ultrasound if uncertain.
Time frame: 6 months after surgery
Postoperative complication rates
Incidence of seroma, hematoma, surgical site infection, and other adverse events
Time frame: Up to 6 months after surgery
Patient satisfaction
The Patient Satisfaction Scale assessing patient satisfaction with the surgical outcome. Scores range from 0 to 100. Higher scores indicate greater satisfaction.
Time frame: 1 month and 6 months after surgery
Operative time
Total operative time from skin incision to closure, measured in minutes.
Time frame: Perioperative
Postoperative hospital stay
Cumulative length of hospital stay from the date of surgery until the 6-month follow-up, measured in days. This includes the initial postoperative stay and any re-hospitalizations related to the inguinal hernia or its surgical repair (e.g., due to recurrence, infection, seroma, hematoma, or other mesh-related complications).
Time frame: up to 6 months
Plan to share: Yes — Individual participant data (IPD) that underlie the results reported in the primary publication will be shared after de-identification. The study protocol, statistical analysis plan, and informed consent form will also be shared.
Supporting information: Study protocol, Statistical analysis plan, Informed consent form
Time frame: Data will be available beginning 6 months after publication of the primary results.
Access criteria: Data will be made available to researchers who provide a methodologically sound proposal, for purposes of achieving the aims in the approved proposal. Proposals should be directed to the corresponding author.
No publications or documents are linked to this record.
Start is estimated for Jun 2026; primary completion for Dec 2027, 18 months later.
Of 179 non-industry interventional studies with no phase under Hernia, Inguinal, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 35. This study's planned 18 months is close to that.
Counting every sponsor, half of 188 studies reached it within 19 months; a quarter within 9 and three quarters within 36.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Xiangya Hospital of Central South University →